Prophylaxis with the novel immunomodulator pidotimod reduces the frequency and severity of upper respiratory tract infections in children with Down's syndrome

Journal of Chemotherapy

Volumn 11, Issue 2, 1999, Pages 126-130

  La Mantia, I ^b   Grillo, C ^b   Mattina, T ^b   Zaccone, P ^b   Xiang, M ^b   Di Mauro, M ^b   Meroni, P L ^a   Nicoletti, F ^b  

^a HS Raffaele   (Italy)

^b NONE

Author keywords

Down's syndrome; Immunomodulator; Pidotimod; Respiratory tract infection

Indexed keywords

PIDOTIMOD;

ADOLESCENT; ARTICLE; CHEMOPROPHYLAXIS; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DOWN SYNDROME; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; FEVER; HUMAN; IMMUNOMODULATION; MALE; ORAL DRUG ADMINISTRATION; RECURRENT DISEASE; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

EID: 0032954739     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1999.11.2.126     Document Type: Article

References (22)

1. 1 Siegel M. Susceptibility of mongoloids to infection. I. Incidence of penumonia, influenza A and Shigella dysenteriae (Sonne). Am J Hyg 1948; 48: 53-62.
2. 2 Oster J, Mikkelsen M, Nielsen A. Mortality and life table of Down's syndrome. Acta Paediatr Scand, 1975; 64: 322-326.
3. 3 Gupta S, Fikrig SM, Mariano E, Quazi G. Monoclonal antibody defined T cell subsets and autologous mixed lymphocyte reaction in Down's syndrome. Clin Exp Immunol 1983; 53: 25-30.
4. 4 Franceschi C, Licastro F, Paolucci P, Masi M, Cavicchi S, Zannotti M. T and B lymphocyte subpopulations in Down's syndrome: A study of noninstitutionalized subjects. J Ment Defic Res 1978; 22: 179-191.
5. 5 Burgio GR, Ugazio AG, Nespoli L, Marcioni AE, Bottelli AM, Pasquali F. Derangements of immunoglobulin levels, phytohemagglutinin responsiveness and T and B cell markers in Down's syndrome at different ages. Eur J Immunol 1975; 5: 600-605.
6. 6 Philip R, Berger AC, McManus NH, Warner NH, Peacock MA, Epstein LB. Abormalities of the in vitro cellular and humoral responses to tetanus and influenzae antigens with concomitant numerical alterations in lymphocyte subsets in Down syndrome (trisomy 21). J Immunol 1986; 136: 1661-1667.
7. 7 Gerez L, Madar L, Arad G, et al. Aberrant regulation of interleukin-2 but not interferon-γ gene expression in Down syndrome (trisomy 21). Clin Immunol Immunopathol 1991; 58: 251-266.
8. 8 Costarizza A, Ortolani C, Forti E, et al. Age-related expansion of functionally inefficient cells with markers of natural killer activity in Down's syndrome. Blood, 1991; 77: 1263-1270.
9. 9 Nespoli L, Burgio GR, Ugazio AG, Maccario R. Immunological features of Down's syndrome: a review. J Intellect Disabil Res 1993; 37(Pt6): 543-551.
10. 10 Pugliese A, Biglino A, Uslenghi C, et al. Evaluation of the effect of pidotimod on the immune system. Int J Immunother 1992; VIII: 212-219.
11. 11 Borghi MO, Fain C, Barcellini W, et al. Ex vivo effect of pidotimod on peripheral blood mononuclear cell immune functions: study of an elderly population. Int J Immunother 1994; X: 35-39.
12. 12 Migliorati G, D'Adamio L, Coppi G, Nicoletti I, Riccardi C. Pidotimod stimulates natural killer cell activity and inhibits thymocyte cell death. Immunopharmacol Immunotoxicol 1992; 14: 737-748.
13. 13 Evaluation of the kinetics of the immunomodulating activity of pidotimod on human phagocytes. Int J Immunother 1993; IX: 207-210.
14. 14 Coppi G, Falcone A, Manzardo S. Protective effects of pidotimod against experimental bacterial infections in mice. Arzneim-Forsch/Drug Res 1994; 44, 12a: 1417-1421.
15. 15 Di Marco R, Condorelli F, Girardello R, et al. Increased rate of survival in Streptococcus pneumoniae infected rats treated with the new immunomodulator pidotimod. Scand J Infect Dis 1992; 24: 821-823.
16. 16 Dianzani C, Colangelo D, Tonso E, Guidotto S, Viano I. In vivo antiviral effects of pidotimod. Arzneim-Forsch/Drug Res 1994; 44: 12a, 1431-1433.
17. 17 Careddu P, Alfano S, Zavattini G. Pidotimod in the prophylaxis of recurrent acute tonsillitis in childhood. Adv Ther 1992; 9: 174-183.
18. 18 Caramia G, Clemente E, Solli R, et al. Efficacy and safety of pidotimod in the treatment of recurrent respiratory infections in children. Arzneim-Forsch/Drug Res 1994; 44, 12a: 1480-1484.
19. 19 Passali D, Calearo C, Conticello S, and a multicenter trial group. Pidotimod in the management of recurrent pharyngotonsillar infections in children. Arzneim-Forsch/Drug Res 1994; 44, 12a: 1511-1516.
20. 20 Pozzi E, Dolcetti A, Orlandi O, et al. Pidotimod in the treatment of patients affected by bacterial exacerbations of chronic bronchitis. Arzneim-Forsch/Drug Res 1994; 44, 12a: 1495-1498.
21. 21 Bisetti A, Ciappi G, Bariffi F, et al. Evaluation of the efficacy of pidotimod in the exacerbations in patients affected with chronic bronchitis. Arzneim-Forsch/Drug Res 1994; 44, 12a: 1499-1502.
22. 22 Motta G, De Campora E, De Vita C, et al. Immunoactivity of pidotimod against episodes of recurrent tonsillitis in childhood. Arzneim-Forsch/Drug Res 1994; 44, 12a: 1521-1524.